Search clinical trials for: CC-99712

Total 829 results

Celgene

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects

Healthy Volunteer

United Kingdom
Celgene

Terminated

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Discoid Lupus

United States
Celgene

Terminated

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Healthy Volunteers | Parapsoriasis

United States
University of Washington
Patient-Centered Outcomes Research Institute

Completed

Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study (MS-CARE)

Depression | Pain | Multiple Sclerosis

United States
University of Houston

Recruiting

Dual Use Approach Bias Training for Nicotine Addiction

Tobacco Smoking | Electronic Cigarette Use | Substance Use

United States
Philip Morris Products S.A.

Completed

Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks

Smoking

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation

Completed

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Prostate Cancer | Castration Resistant Prostate Cancer

United States
Celgene

Completed

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

Healthy Volunteer

United States
Celgene

Completed

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

Healthy Volunteer

United States
Philip Morris Products S.A.

Completed

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

Smoking

United States
Celgene

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

Healthy Volunteers

United States
Celgene Corporation

Completed

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Healthy Volunteers

United States
Celgene

Completed

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, United Kingdom
Celgene

Terminated

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis (AS SpA axSpA)

Spondylitis, Ankylosing

United States, China, Czechia, Germany, Poland, Romania, Spain, Turkey
Celgene

Terminated

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Pathologic Processes | Fibrosis | Respiratory Tract Diseases | Lung Diseases | Idiopathic Pulmonary Fibrosis | Lung Diseases, Interstitial | Idiopathic Interstitial Pneumonias

United States, Australia, Colombia, United Kingdom, Russian Federation, Brazil, Germany, Canada, Greece, Romania, Taiwan, Turkey, Ukraine
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.

Smoking

Poland
Celgene

Completed

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Renal Insufficiency

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.

Healthy Volunteers

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Psoriasis

United States, Canada
Celgene

Completed

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

United States
Celgene

Terminated

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Fibrosis | Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Diseases, Interstitial | Interstitial Lung Disease

United States, Canada
Celgene Corporation

Completed

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Healthy Volunteers

United States
Nobel Biocare
Charite University, Berlin, Germany

Unknown

A Clinical Evaluation of NobelProcera Implant Bar Overdenture

Edentulous

Germany, Italy
Afyonkarahisar Health Sciences University

Completed

Efficacy of Ultrasound-Guided Hydrodissection in Carpal Tunnel Syndrome

Musculoskeletal Diseases | Carpal Tunnel Syndrome | Median Nerve Disease | Ultrasound-Guided Injection

Turkey
Celgene

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Australia, Spain, Canada, United Kingdom
The University of Texas Health Science Center,...
Children and Youth with Special Health Care Needs National Research Network...

Recruiting

An Enhanced Home-Based Telemedicine Program Using Remote Examination Devices for Children With Medical Complexity

Chronic Diseases in Children

United States
Hospices Civils de Lyon

Not yet recruiting

Assessment of One-shot Cardiac-cervical-intracranial MRI in the Etiological Work up of Ischemic Stroke and Transient Ischemic Attacks (Concise)

Ischemic Stroke | Transient Ischemic Attack

France
Cocrystal Pharma, Inc.
Cocrystal Pharma Australia Pty Ltd.; Linear Clinical Research

Completed

CC-42344 Safety Study in Healthy Participants

Influenza A

Australia
St. Luke's Health System, Boise, Idaho
Patient-Centered Outcomes Research Institute; University of Washington; Idaho...

Completed

Mental Health Among Patients, Providers, and Staff During the COVID-19 Era (MHAPPS)

Covid19 | Mental Health

United States
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Renal Impairment

United States
Bristol-Myers Squibb
Celgene

Completed

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Healthy Volunteers

United States
University of Wisconsin, Madison
National Cancer Institute (NCI); American Cancer Society, Inc.

Completed

A Community Based Approach to Reducing Rural Cancer Disparities, Aim 2

Cancer

United States
University of Colorado, Denver
Bristol-Myers Squibb

Recruiting

CC-486 and Venetoclax for Acute Myeloid Leukemia

AML

United States
Tel Hai College
Saint Vincent De Paul - French Hospital - Nazareth

Recruiting

The Effect of Energy Drinks Consumption on Acute Physiological and Psychological Responses of Israeli Arab Adolescents (EDE)

Energy Drinks

Israel
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Bristol-Myers Squibb

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Relapsed or Refractory T-cell Lymphomas

Japan
Bristol-Myers Squibb

Completed

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Hepatic Impairment

United States
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.

Smoking

Poland
VA Office of Research and Development

Completed

Optimizing Dementia Care (ODeC)

Dementia | Dementia, Vascular | Alzheimer's Disease | Caregivers | Veterans

United States
MiMedx Group, Inc.

Terminated

Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis (dHACM)

Plantar Fasciitis

United States
Nobel Biocare

Recruiting

A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

Marginal Bone Level Change

Denmark
Celgene

Recruiting

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

Healthy Volunteers

United States
University of Michigan Rogel Cancer Center

Recruiting

CLEAR Care Companion Application

Bladder Cancer | Radical Cystectomy

United States
Celgene

Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

Healthy Volunteers

Belgium
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Biomarkers of Exposure Study (ZRHX-EX-01)

Smoking

Poland
University of Alberta

Completed

Chest Compression and Sustained Inflation

Newborn Infants Having Asystole or Bradycardia at Birth

Canada
Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Completed

New Cross Linked Hyaluronan Gel After Deep Infiltrating Endometriosis Surgery (HYALOENDOQoL)

Quality of Life | Endometriosis | Surgery | Adhesion
Dana-Farber Cancer Institute
Stand Up To Cancer

Active, not recruiting

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Lymphoma | Solid Tumor, Childhood | Brain Tumor, Pediatric

United States, Canada
Medical College of Wisconsin

Withdrawn

Preoperative Self-managed Respiratory Therapy for Reduction of Postoperative Pulmonary Complications (PRESMART)

Postoperative Respiratory Complication

United States
Celgene

No longer available

Expanded Access for AG-221

Acute Myeloid Leukemia

United States

3

Subscribe